REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

/PRNewswire/ -- Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible...

Related Keywords

United States ,American ,Dana Cormack ,Chris Brinzey ,Ultragenyx Pharmaceutical Inc ,Technology Platform ,Technology Platform Licensees ,Drug Administration ,American Academy Of Ophthalmology ,Rocket Pharmaceuticals Inc ,Nasdaq ,Novartis ,Technology Licensee Program ,Development Expenses ,Exchange Commission ,Corporate Communications ,Securities Exchange ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Chief Executive Officer ,Investigational New Drug ,Biologics Licensing Application ,Duchenne Muscular Dystrophy ,Hunter Syndrome ,Good Manufacturing Practice ,Manufacturing Facility ,Licensee Program ,Rocket Pharmaceuticals ,Ultragenyx Pharmaceutical ,Ornithine Transcarbamylase ,Administrative Expenses ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Regenxbio Inc ,